Clinical trial
A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma
NCT03590574 is registered in ClinicalTrials.gov with Autolus Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Arm, Open Label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO4, a CAR T-cell Treatment Targeting TRBC1, in Patients With Relapsed or Refractory TRBC1 Positive Selected T Cell Non-Hodgkin Lymphoma
- Lead sponsor
- Autolus Limited
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- August 30, 2018
- Completion date
- December 12, 2024
- Enrollment
- 20 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, peripheral t-cell lymphoma, not otherwise specified, t cell non-hodgkin lymphoma